Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):
- CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML)1
- Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL)2
- Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)3
Currently, there are 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies.
TAP Portfolio Assets in Continuing Development
1approved on August 3 2017 with clinical data published: J Clin Oncol. 2018 Sep; 36(26): 2684–2692 2approved on October 18 2017 with clinical data published: Lancet Oncol. 2019 Jan; 20(1): 31–42 3approved on December 21 2018 with clinical data published: N Engl J Med. 2019 Apr; 380(17): 1628–1637